HomeCompareJIAXF vs ABBV

JIAXF vs ABBV: Dividend Comparison 2026

JIAXF yields 3.37% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 JIAXF wins by $737.86M in total portfolio value· pulled ahead in Year 2
10 years
JIAXF
JIAXF
● Live price
3.37%
Share price
$4.54
Annual div
$0.15
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$737.96M
Annual income
$698,128,027.74
Full JIAXF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — JIAXF vs ABBV

📍 JIAXF pulled ahead of the other in Year 2

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodJIAXFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, JIAXF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
JIAXF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

JIAXF
Annual income on $10K today (after 15% tax)
$286.17/yr
After 10yr DRIP, annual income (after tax)
$593,408,823.58/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, JIAXF beats the other by $593,387,767.57/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of JIAXF + ABBV for your $10,000?

JIAXF: 50%ABBV: 50%
100% ABBV50/50100% JIAXF
Portfolio after 10yr
$369.03M
Annual income
$349,076,399.75/yr
Blended yield
94.59%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

JIAXF
No analyst data
Altman Z
4.0
Piotroski
6/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

JIAXF buys
0
ABBV buys
0
No recent congressional trades found for JIAXF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricJIAXFABBV
Forward yield3.37%3.06%
Annual dividend / share$0.15$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%40.6%
Portfolio after 10y$737.96M$102.3K
Annual income after 10y$698,128,027.74$24,771.77
Total dividends collected$735.06M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: JIAXF vs ABBV ($10,000, DRIP)

YearJIAXF PortfolioJIAXF Income/yrABBV PortfolioABBV Income/yrGap
1$11,373$673.35$11,550$430.00$177.00ABBV
2← crossover$13,601$1,431.44$13,472$627.96+$129.00JIAXF
3$17,753$3,199.64$15,906$926.08+$1.8KJIAXF
4$26,802$7,806.22$19,071$1,382.55+$7.7KJIAXF
5$50,706$22,028.46$23,302$2,095.81+$27.4KJIAXF
6$132,154$77,898.81$29,150$3,237.93+$103.0KJIAXF
7$520,893$379,488.21$37,536$5,121.41+$483.4KJIAXF
8$3,353,193$2,795,837.49$50,079$8,338.38+$3.30MJIAXF
9$37,228,842$33,640,924.97$69,753$14,065.80+$37.16MJIAXF
10$737,962,889$698,128,027.74$102,337$24,771.77+$737.86MJIAXF

JIAXF vs ABBV: Complete Analysis 2026

JIAXFStock

Jiangxi Copper Company Limited engages in exploring, mining, smelting, and refining copper in Mainland China, Hong Kong, and internationally. It offers copper cathodes, copper rods and wires, sulphuric acid, and other products, as well as deposit, loan, guarantee, and financing consultation services. It is involved in the processing and sale of copper and hardware electric products; production and sale of non-ferrous metals, rare metals and non-metals, electrolytic copper foil, spiral and copper tubes, copper and enameled wires, other copper pipe products, and cast iron grinding balls; provision of repair, consulting, and transportation services; exploration, mining, selection, and smelting of gold and chemical; project, industrial, and fund investment, investment management, and investment and economic information advisory services; metallurgical chemistry; equipment manufacturing and maintenance activities; and development and production of thermo-electronic semiconductors and appliances. In addition, it engages in the development of chemical technologies; contracting for mining constructions; production and sale of casting products; maintenance of mechanical and electrical equipment; installation and debugging of equipment; sale of building materials; production of copper sulfate and electrolytic copper; scrap of base metals; and geological investigation and survey, and construction and engineering measurement. Further, it is involved in the sale of mineral processing, fine chemical, and other industrial and domestic products; trading of metal products; machinery processing; manufacture and sale of wear resistant materials; and trade and settlement of import-export business, offshore investment and financing, cross-border RMB settlement, and research and development activities. The company was founded in 1979 and is headquartered in Nanchang, China.

Full JIAXF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this JIAXF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

JIAXF vs SCHDJIAXF vs JEPIJIAXF vs OJIAXF vs KOJIAXF vs MAINJIAXF vs JNJJIAXF vs MRKJIAXF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.